FEB 0 4 2000

EXPRESS MAIL NO. EL514779718US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 1 U 2000 2/10/03

In re application of:

Patricia D. MURPHY et al.

Application Serial No. 09/084,471

Filed: May 22, 1998

For:

NOVEL CODING SEQUENCE HAPLOTYPES OF THE HUMAN

BRCA2 GENE

Art Unit: 1655

Examiner: Zitomer, S.

Attorney's Docket No. 53710031US02

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Supplemental Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Supplemental PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

	Applic	eants have checked the appropriate boxes below.	
1 .	This S	upplemental Information Disclosure Statement is being filed within three	
	month	s of the U.S. filing date OR before the mailing date of a first Office Action on	
	the me	erits. No statement under 37 C.F.R. § 1.97(e) or fee is required. I hereby state	
	that ea	ch item of information contained in this Supplemental Information Disclosure	
	Staten	nent was cited in a communication from a foreign patent office in a counterpart	
	foreign	a application	
□ 2.	This Information Disclosure Statement is being filed more than three months after		
	the U.S. filing date AND after the mailing date of the first Office Action on the		
	merits, but before the mailing date of a Final Rejection or Notice of Allowance.		
	□ a.	I hereby state that each item of information contained in this Information	
		Disclosure Statement was cited in a communication from a foreign patent	
		office in a counterpart foreign application not more than three months prior	
		to the filing of this Information Disclosure Statement. 37 C.F.R.	
		§ 1.97(e)(1).	
	□ в.	I hereby state that no item of information in this Information Disclosure	
		Statement was cited in a communication from a foreign patent office in a	
		counterpart foreign application, and, to my knowledge after making	
		reasonable inquiry, no item of information contained in this Information	
		Disclosure Statement was known to any individual designated in 37 C.F.R.	
		§ 1.56(c) more than three months prior to the filing of this Supplemental	
		Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).	
	□ c.	Attached is our Check No in the amount of \$ in payment	
		of the fee under 37 C.F.R. § 1.17(p).	
□ 3.	This Information Disclosure Statement is being filed more than three months after		
	the U.S. filing date and after the mailing date of a Final Rejection or Notice of		
	Allowance, but before payment of the Issue Fee. It is hereby requested that the		
	Inform	nation Disclosure Statement be considered. Attached is our Check No.	
		in the amount of \$ in payment of the fee under 37 C.F.R. § 1.17(i).	
	□ a.	I hereby state that each item of information contained in this Information	
		Disclosure Statement was cited in a communication from a foreign patent	
		office in a counterpart foreign application not more than three months prior	
		to the filing of this Information Disclosure Statement. 37 C.F.R.	
		§ 1.97(e)(1).	

□ b.

I hereby state that no item of information in this Information Disclosure

Statement was cited in a communication from a foreign patent office in a





counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

	Disclosure Statement. 37 C.F.R. § 1.97(e)(2).		
□ 4.	Relevance of the non-English language document(s) is discussed in the present specification.		
□ 5.	The document(s) was/were cited in a corresponding foreign application. An English		
_	language version of the foreign search report is attached for the Examiner's		
	information.		
□ 6.	A concise explanation of the relevance of the non-English language document(s)		
- 0.	appears below:		
□ 7.	The Examiner's attention is directed to co-pending U.S. Patent Application No.		
— /.	, filed, which is directed to related technical subject matter.		
	The identification of this U.S. Patent Application is not to be construed as a waiver		
	of secrecy as to that application now or upon issuance of the present application as a		
	patent. The Examiner is respectfully requested to consider the cited application and		
	the art cited therein during examination.		
□ 8.	Copies of the documents were cited by or submitted to the Office in Application No.		
- 0.	, filed, which is relied upon for an earlier filing date under		
	35 S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R.		
	§ 1.98(d).		
C 1	It is respectfully requested that the Examiner initial and return a copy of the enclosed		
	mental PTO-1449, and to indicate in the official file wrapper of this patent application		
that the	documents have been considered.		
	The U.S. Patent and Trademark Office is hereby authorized to charge any fee		
deficie	ncy, or credit any overpayment, to our Deposit Account No. 08-3038.		
	Respectfully submitted,		
Date: 1	February 3, 2000 Albert P. Halluin (Reg. No. 25,227)		
***	NOVE A CONTRACT		

HOWREY & SIMON

Box No. 34 1299 Pennsylvania Avenue, N.W. Washington, D.C. 20004-2402 (650) 463-8100